How Pharmaceuticals trying to cut costs without compromising compliance are overlooking chances to better manage risks*

The Global State of Information Security 2007

It's a matter of prioritisation. As margins shrink, pipelines thin and generic competition heats up, rising cost pressures are forcing pharmaceutical executives to confront difficult choices on which investments in information security will deliver the most valuable impacts to performance and profitability. Not unexpectedly, compliance-related initiatives top the list. This year, the vast majority of pharmaceutical and life sciences respondents to the Global State of Information Security 2007, the world's largest survey on privacy and information security practices, confirm that complying with regulations is the single most important business issue driving security spending (79% vs. 54%, the cross-industry average).

•   Download How Pharmaceuticals trying to cut costs without compromising compliance are overlooking chances to better manage risks* (155kb)